Skip to content

Acute Effects of Tolvaptan on Acute Exacerbation of Chronic Heart Failure

Acute Effects of Tolvaptan on Acute Exacerbation of Chronic Heart Failure - ACT-HF

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000012439
Enrollment
30
Registered
2013-11-29
Start date
2013-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure

Interventions

treatment with oral topvaptan treatment with carperitide and fulosemide injection

Sponsors

Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) NYHA class II or III heart failure patient with volume overload 2) patient who can take medicine orally 3) patient who's systolic blood pressure is 90 mmHg or more at hospital admission 4) patient who is at least 20 years old when he or she agreed to this study 5) patient who agreed within 24 hours after hospital admission

Exclusion criteria

Exclusion criteria: 1) heart failure patient by coronary artery disease 2) patient who has allergic past history to tolvaptan or relative chemicals 3) patient of no urine production 4) patient who do not feel thirsty or have difficulty to take water orally 5) patient who is hypernatremia 6) patient who is pregnant or might be pregnant 7) patient who is very low blood pressure or cardiogenic shock state 8) patient who suffers right ventricular myocardial infarction 9) patient who have dehydration 10) patient who is assessed to be inappropriate for the study by study investigators

Design outcomes

Primary

MeasureTime frame
Average urinary volume in a day and body weight change, at fifth or the last day of the treatment

Secondary

MeasureTime frame
1) NT-proBNP; before and fifth or the last day of the treatment 2) serum Na, K, creatinie; before and fifth or the last day of the treatment 3) IVC diameter by echocardiography; before and fifth or the last day of the treatment 4) urinary osmorarity; before and fifth or the last day of the treatment 5) oxidative stress marker change; serum and urine 6) event frequency during 90 days after hospital discharge 7) cost of heart failure treatment during hospital admission; cost of treatment or admission fee

Countries

Japan

Contacts

Public ContactYuji Koide

Nagasaki University Hosital Cardiovascular Medicien

ykoide1@nagasaki-u.ac.jp+81-95-819-7288

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026